PCVX
PCVX clinical trials: Vaxcyte, Inc.
Every trial on ClinicalTrials.gov where Vaxcyte, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 9
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PCVX on the catalyst calendar · PCVX registry changes
- Primary completion Oct 25, 2026ActualPhase 3NCT07425392Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationVaxcyte, Inc. · Pneumococcal DiseaseCompletedPCVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 21, 2026ActualPhase 3NCT07365826A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeVaxcyte, Inc. · Pneumococcal DiseaseCompletedPCVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 17, 2026ActualPhase 3NCT07284654Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49Vaxcyte, Inc. · Pneumococcal DiseaseCompletedPCVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1NCT07616934A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young AdultsVaxcyte, Inc. · Group A Streptococcal InfectionRecruitingPCVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT06720038A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy InfantsVaxcyte, Inc. · Pneumococcal VaccinesActive, not recruitingPCVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 25, 2025ActualPhase 2NCT05844423Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy InfantsVaxcyte, Inc. · Pneumococcal VaccinesCompletedPCVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 17, 2024ActualPhase 1/Phase 2NCT06151288Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in AdultsVaxcyte, Inc. · Pneumococcal VaccinesCompletedPCVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2023ActualPhase 2NCT05297578Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older AdultsVaxcyte, Inc. · Pneumococcal VaccinesCompletedPCVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 10, 2023ActualPhase 1/Phase 2NCT05266456Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in AdultsVaxcyte, Inc. · Pneumococcal VaccinesCompletedPCVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner